Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

982 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation.
Sakoda T, Kikushige Y, Irifune H, Kawano G, Harada T, Semba Y, Hayashi M, Shima T, Mori Y, Eto T, Kamimura T, Iwasaki H, Ogawa R, Yoshimoto G, Kato K, Maeda T, Miyamoto T, Akashi K. Sakoda T, et al. Among authors: akashi k. Cancer Sci. 2024 Dec 26. doi: 10.1111/cas.16431. Online ahead of print. Cancer Sci. 2024. PMID: 39726280 Free article.
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Mori Y, Takizawa J, Katsuoka Y, Takezako N, Nagafuji K, Handa H, Kuroda J, Sunami K, Kamimura T, Ogawa R, Kikushige Y, Harada M, Akashi K, Miyamoto T; Japan Study Group for Cell Therapy and Transplantation. Mori Y, et al. Among authors: akashi k. Cancer Sci. 2024 Jun;115(6):2002-2011. doi: 10.1111/cas.16158. Epub 2024 Mar 18. Cancer Sci. 2024. PMID: 38498976 Free PMC article. Clinical Trial.
A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.
Takigawa K, Kawano N, Mori Y, Yamauchi T, Tochigi T, Miyawaki K, Mori K, Shimo M, Nakaike T, Yamashita K, Mashiba K, Kikuchi I, Marutsuka K, Ohshima K, Kato K, Akashi K. Takigawa K, et al. Among authors: akashi k. Blood Cell Ther. 2024 Mar 29;7(2):37-40. doi: 10.31547/bct-2023-032. eCollection 2024 May 25. Blood Cell Ther. 2024. PMID: 38854403 Free PMC article.
Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.
Uchida M, Ishida S, Mochizuki E, Ozawa N, Yonemitsu H, Ochiai H, Nakamura H, Kawashiri T, Watanabe H, Tsuji T, Suetsugu K, Kato K, Egashira N, Akashi K, Ieiri I. Uchida M, et al. Among authors: akashi k. Cancer Diagn Progn. 2024 Sep 1;4(5):617-622. doi: 10.21873/cdp.10372. eCollection 2024 Sep-Oct. Cancer Diagn Progn. 2024. PMID: 39238617 Free PMC article.
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: akashi k. Int J Hematol. 2024 Jun;119(6):677-685. doi: 10.1007/s12185-024-03738-8. Epub 2024 Mar 22. Int J Hematol. 2024. PMID: 38519820 Clinical Trial.
982 results